Gabapentin Tablet, Film Coated
Product Images NDC 71610-044

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71610 0044 30

Gabapentin 600 mg film-coated tablets label showing product NDC 71610-044-30, with quantity of 30 tablets. The manufacturer is listed as Sashun Limited and labeler as Aphena Pharma Solutions - Tennessee, LLC located in Cookeville, TN. The label includes storage instructions and a barcode.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A text panel displaying the formula for calculating creatinine clearance (CLCr), incorporating patient age, weight, serum creatinine level, and an adjustment factor for female patients. This formula appears to be part of the drug information or dosing considerations for Gabapentin tablets.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin, showing a cyclohexane ring bound to an amino group and a carboxyl group, consistent with the active ingredient gabapentin in the product.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over 8 weeks between placebo and gabapentin (3600 mg/day). The timeline includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a greater reduction in mean pain score for gabapentin compared to placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over seven weeks for placebo and two Gabapentin dosages (1800 mg/day and 2400 mg/day). The x-axis represents weeks with baseline, week 1 to week 7, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain scores from 0 to 10. Gabapentin groups show decreasing pain scores over time compared to placebo.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the percentage of responders for placebo (PBO) and gabapentin (GBP) at various doses in two separate studies. Study 1 shows 12% for placebo and 29% for GBP 3600 mg, while Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance markers are indicated for gabapentin groups.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot showing the percentage difference on the vertical axis and daily dose in mg on the horizontal axis. Data points represent three studies (a, b, c) evaluated at daily doses of 600, 900, 1200, and 1800 mg. Each study is marked with different symbols and letters, illustrating variations across doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.